James P. Mullaney Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James Mullaney IBIO stock SEC Form 4 insiders trading

James has made over 1 trades of the iBio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently James exercised 11,250 units of IBIO stock worth $10,463 on 27 May 2020.

The largest trade James's ever made was exercising 11,250 units of iBio Inc stock on 27 May 2020 worth over $10,463. On average, James trades about 5,625 units every 0 days since 2019.

You can see the complete history of James Mullaney stock trades at the bottom of the page.

What's James Mullaney's mailing address?

James's mailing address filed with the SEC is C/O IBIO, INC., 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022.

Insiders trading at iBio Inc

Over the last 13 years, insiders at iBio Inc have traded over $99,626,328 worth of iBio Inc stock and bought 15,716,013 units worth $10,660,994 . The most active insiders traders include Capital Ltd Portfolio Servi..., Carl Desantis und William D Clark. On average, iBio Inc executives and independent directors trade stock every 98 days with the average trade being worth of $1,893,515. The most recent stock trade was executed by Martin Brenner on 1 November 2023, trading 4,881 units of IBIO stock currently worth $1,318.

What does iBio Inc do?

ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.

Complete history of James Mullaney stock trades at iBio Inc

iBio Inc executives and stock owners

iBio Inc executives and other stock owners filed with the SEC include:

• Thomas Isett,
  Chairman of the Board, Chief Executive Officer
• Thomas F. Isett III,
  CEO, Pres & Chairman
• Robert Kay,
  Interim Secretary, Interim Treasurer, Director
• Randy Joe Maddux,
  Chief Operating Officer
• Dr. Martin B. Brenner D.V.M., Ph.D.,
  Chief Scientific Officer
• Robert Erwin,
  President
• Robert B. Kay,
  Interim Sec. & Interim Treasurer
• James Hill,
  Independent Director
• John McKey,
  Independent Director
• Seymour Flug,
  Independent Director
• Glenn Chang,
  Independent Director
• Stephen Kilmer,
  Investor Relations
• Gary Sender,
  Independent Director
• Alexandra Kropotova,
  Independent Director
• Linda Armstrong,
  Independent Director
• John Delta,
  Principal Financial Officer, Principal Accounting Officer
• Carlos Picosse,
  Chief Exec. Officer of IBio Brazil
• Dr. Melissa Berquist Ph.D.,
  VP and Head of Vaccines & Animal Health
• Lisa Middlebrook,
  Chief HR Officer
• Robert Matthew Lutz,
  Chief Financial & Bus. Officer
• Mark A Giannone,
  Chief Financial Officer
• Kenneth Bryan Dart,
  10% owner
• Carl Desantis,
  10% owner
• Philip K. Russell,
  Director
• Arthur Y Elliott,
  Director
• Capital Ltd Portfolio Servi...,
  
• Ryan E Terence,
  Chief Scientific Officer
• Randy Joe Maddux,
  Chief Operating Officer
• Robert Matthew Lutz,
  See Remarks
• James P. Mullaney,
  Chief Financial Officer
• Evert B. Schimmelpennink,
  Director
• E Gerald Kay,
  10% owner
• Jules A. Musing,
  Director
• William D Clark,
  Director
• Martin Brenner,
  See Remarks
• Felipe Duran,
  Chief Financial Officer